NEUROCRINE BIOSCIENCES INC

NBIX

NEUROCRINE BIOSCIENCES INC

NBIX

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-29Shares Purchased (TTM):0Shares Sold (TTM):567,592

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:91,721,782Shares Outstanding:100,500,000Institutional Ownership Pct.:91.27%

Earnings Market Reaction:

Filing Date:2026-05-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Biological Products, (No Diagnostic Substances)

AMGN GILD SCLX BIIB MRNA RVMD

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	267	713	340	264	194	233	349	140	396	251	294	160
Available For Sale Securities Debt Securities Curr…	1,050	767	775	712	749	843	879	899	814	781	801	817
Accounts Receivable Net Current	768	687	728	596	516	479	481	468	451	439	418	388
Receivables Net Current	-	-	-	-	-	-	-	-	-	439	-	-
Inventory Net	65	69	69	57	59	57	46	43	37	38	29	32
Prepaid Expense Current	225	171	178	-	-	49	-	-	-	-	-	-
Other Assets Current	63	116	68	121	119	64	122	120	101	98	108	101
Assets Current	2,436	2,523	2,158	1,749	1,638	1,725	1,877	1,670	1,799	1,607	1,650	1,497
Deferred Income Tax Assets Net	381	320	369	537	499	486	454	420	378	363	383	379
Available For Sale Securities Debt Securities Nonc…	1,331	1,063	999	874	815	740	644	638	700	688	455	343
Operating Lease Right Of Use Asset	447	455	469	492	502	509	257	263	271	277	81	84
Equity Securities Fv Ni Current And Noncurrent	146	121	118	88	94	125	127	144	164	162	133	173
Property Plant And Equipment Net	91	90	97	92	87	83	80	80	75	71	69	66
Intangible Assets Net Excluding Goodwill	-	-	36	37	36	37	35	34	34	36	35	37
Other Assets Noncurrent	74	60	20	22	15	52	62	58	51	50	43	36
Assets	4,906	4,632	4,266	3,890	3,688	3,719	3,535	3,305	3,472	3,251	2,848	2,613
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	773	674	584	490	475	462	393	359	417	449	503	392
Convertible Debt Current	-	-	-	-	-	0	0	0	123	170	170	170
Embedded Derivative Fair Value Of Embedded Derivat…	-	-	-	-	-	-	-	-	136	-	-	-
Other Liabilities Current	59	69	54	57	48	46	37	40	37	36	19	21
Liabilities Current	832	743	638	546	523	508	430	399	713	655	692	583
Operating Lease Liability Noncurrent	406	415	428	439	448	455	251	256	253	258	86	89
Other Liabilities Noncurrent	261	220	196	210	182	166	135	141	121	106	69	89
Liabilities	1,499	1,378	1,262	1,196	1,152	1,129	816	796	1,086	1,019	846	760
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	2,817	2,792	2,696	2,597	2,532	2,555	2,623	2,555	2,496	2,382	2,309	2,242
Accumulated Other Comprehensive Income Loss Net Of…	0	13	13	13	9	6	15	3	3	7	-2	-1
Retained Earnings Accumulated Deficit	590	448	294	85	-5	29	81	-49	-114	-157	-305	-388
Stockholders Equity	3,407	3,253	3,004	2,694	2,536	2,590	2,719	2,509	2,386	2,232	2,002	1,853
Liabilities And Stockholders Equity	4,906	4,632	4,266	3,890	3,688	3,719	3,535	3,305	3,472	3,251	2,848	2,613
Debt Instrument Face Amount	-	-	-	-	-	-	-	-	170	-	-	-
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	220	220	220	220	220	220	220	220	220	220	220	220
Common Stock Shares Issued	101	100	100	99	99	99	101	101	101	99	98	98
Shares Outstanding	101	100	100	99	99	99	101	101	101	99	98	98

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	17.21%	24.77%	30.14%	-	-	-	-	-	-	-	-	-
2025	12.09%	14.28%	20.40%	-0.97%	6.19%	2.43%	-3.77%	-1.61%	-10.17%	-6.77%	-4.25%	-4.12%
2024	-2.54%	-5.91%	1.86%	-0.22%	-22.72%	-22.94%	1.06%	8.92%	15.23%	-4.86%	-19.49%	-7.68%
2023	-	-	-	3.94%	9.96%	6.77%	1.11%	15.78%	23.82%	-0.76%	4.25%	2.79%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	2.93	3.39	3.38	3.20	3.13	3.40	4.37	4.19	2.52	2.45	2.39	2.57
Quick Ratio	2.58	3.07	3.00	3.10	3.02	3.19	4.26	4.08	2.47	2.40	2.34	2.51
Working Capital	1.60B	1.78B	1.52B	1.20B	1.12B	1.22B	1.45B	1.27B	1.09B	952.20M	958.30M	914.10M
Leverage & Debt
Debt to Equity	0.44	0.42	0.42	0.44	0.45	0.44	0.30	0.32	0.46	0.46	0.42	0.41
Interest Coverage TTM	-	-	-	-	-	518.64	263.09	162.48	100.96	54.54	44.35	32.04
Debt Ratio	0.31	0.30	0.30	0.31	0.31	0.30	0.23	0.24	0.31	0.31	0.30	0.29
Efficiency & Turnover
Asset Turnover TTM	0.72	0.69	0.69	0.70	0.67	0.68	0.70	0.72	0.68	0.67	0.71	0.72
Days Sales Outstanding TTM	75.54	74.38	82.25	77.36	73.13	71.16	73.14	73.69	77.56	76.33	73.56	72.72
Receivables Turnover TTM	4.83	4.91	4.44	4.72	4.99	5.13	4.99	4.95	4.71	4.78	4.96	5.02
Per Share Metrics
Diluted EPS TTM	6.47	4.67	4.18	3.45	2.98	3.29	3.70	3.26	3.57	2.47	1.89	1.76
Free Cash Flow Per Share TTM	8.22	7.48	5.97	5.34	4.94	5.55	4.35	4.91	6.16	3.70	3.93	2.84
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	98.17%	98.18%	98.37%	98.49%	98.52%	98.56%	98.52%	98.28%	98.05%	97.90%	97.82%	97.98%
Operating Profit Margin TTM	25.43%	21.64%	20.51%	19.72%	20.51%	24.22%	25.81%	25.30%	23.43%	13.30%	11.44%	9.00%
Net Profit Margin TTM	21.55%	16.73%	15.95%	13.88%	12.68%	14.49%	17.21%	16.00%	18.65%	13.23%	10.71%	10.54%
Growth Metrics
Net Revenue Growth (1Y)	28.59%	21.45%	19.61%	18.42%	21.73%	24.81%	25.72%	26.69%	23.99%	26.76%	28.46%	29.01%
Net Income Growth (1Y)	118.64%	40.23%	10.91%	2.68%	-17.28%	36.68%	102.04%	92.29%	477.66%	61.62%	228.18%	1,345.90%
EPS Growth (1Y)	116.90%	41.50%	12.81%	4.55%	-17.20%	33.01%	95.65%	86.19%	462.03%	58.48%	221.14%	1,316.27%
Valuation Metrics
P/E TTM	19.80	29.49	32.60	35.73	36.06	40.15	30.19	40.91	37.23	51.55	57.66	52.18
P/B TTM	3.89	4.34	4.65	4.62	4.35	5.29	4.28	5.53	5.77	5.77	5.50	4.97
P/S TTM	4.27	4.93	5.20	4.96	4.57	5.82	5.19	6.55	6.94	6.82	6.17	5.50
Market Cap	13.24B	14.11B	13.95B	12.44B	11.03B	13.70B	11.65B	13.88B	13.76B	12.87B	11.01B	9.20B
Enterprise Value	12.97B	14.21B	13.61B	12.17B	10.82B	13.46B	11.29B	13.73B	13.48B	12.78B	10.88B	9.21B
Calculated Values
Free Cash Flow TTM	826.50M	743.90M	593.10M	528.70M	492.20M	557.20M	440.10M	494.60M	614.40M	361.60M	384.70M	277.40M
Net Debt	-274.50M	101.30M	-348.20M	-272.00M	-202.10M	-241.00M	-357.10M	-147.70M	-281.50M	-89.00M	-131.80M	1.50M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-29Sale

Owner: Lippoldt, Darin

Title: Chief Legal Officer

Shares: 9,800

Price/Share: $170.42

Value: $1,670,116.00

Shares Owned: 54,729

Relationship: Officer

Ownership: Direct

2026-06-05Sale

Owner: Sherwin, Stephen A

Title: -

Shares: 25,000

Price/Share: $165.58

Value: $4,139,500.00

Shares Owned: 15,860

Relationship: Director

Ownership: Direct

2026-06-04Sale

Owner: Norwalk, Leslie V

Title: -

Shares: 1,250

Price/Share: $168.06

Value: $210,075.00

Shares Owned: 2,838

Relationship: Director

Ownership: Direct

2026-06-02Sale

Owner: Cooke, Julie

Title: Chief Human Resources Officer

Shares: 36,937

Price/Share: $156.65

Value: $5,786,181.05

Shares Owned: 22,374

Relationship: Officer

Ownership: Direct

2026-06-01Sale

Owner: Onyia, Jude

Title: Chief Scientific Officer

Shares: 11,000

Price/Share: $160.25

Value: $1,762,750.00

Shares Owned: 25,846

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-29	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	9,800	170.42	$1,670,116.00	54,729	4
2026-06-05	Sherwin, Stephen A	Director	-	Direct	Sale	25,000	165.58	$4,139,500.00	15,860	4
2026-06-04	Norwalk, Leslie V	Director	-	Direct	Sale	1,250	168.06	$210,075.00	2,838	4
2026-06-02	Cooke, Julie	Officer	Chief Human Resources Officer	Direct	Sale	36,937	156.65	$5,786,181.05	22,374	4
2026-06-01	Onyia, Jude	Officer	Chief Scientific Officer	Direct	Sale	11,000	160.25	$1,762,750.00	25,846	4
2026-05-29	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	2,261	156.71	$354,321.31	16,225	4
2026-05-27	Onyia, Jude	Officer	Chief Scientific Officer	Direct	Sale	11,000	155.53	$1,710,830.00	25,846	4
2026-05-26	Boyer, David W.	Officer	Chief Corp. Affairs Officer	Direct	Sale	3,888	156.64	$609,016.32	7,799	4
2026-05-19	Gorman, Kevin Charles	Director	-	Direct	Sale	245,088	154.33	$37,824,431.04	511,293	4
2026-05-15	Pops, Richard F	Director	-	Direct	Sale	15,000	157.65	$2,364,750.00	34,480	4
2026-05-12	Norwalk, Leslie V	Director	-	Direct	Sale	3,810	155.01	$590,588.10	2,429	4
2026-01-16	Gano, Kyle	Director,Officer	Chief Executive Officer	Direct	Sale	36,400	132.70	$4,830,280.00	140,407	4
2025-12-16	Norwalk, Leslie V	Director	-	Direct	Sale	1,190	155.09	$184,557.10	6,239	4
2025-12-08	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	4,376	159.65	$698,628.40	43,405	4
2025-12-03	Lyons, Gary A	Director	-	Direct	Sale	15,000	152.61	$2,289,150.00	120,482	4
2025-11-28	Benevich, Eric	Officer	Chief Commercial Officer	Direct	Sale	5,970	151.74	$905,887.80	44,893	4
2025-11-25	Morrow, George J	Director	-	Direct	Sale	15,000	143.37	$2,150,550.00	7,068	4
2025-11-05	Rastetter, William H	Director	-	Direct	Sale	18,000	151.82	$2,732,760.00	40,360	4
2025-11-04	Gano, Kyle	Director,Officer	Chief Executive Officer	Direct	Sale	300	141.97	$42,591.00	140,407	4
2025-08-07	Gorman, Kevin Charles	Director	-	Direct	Sale	106,322	126.41	$13,440,164.02	514,596	4
2025-07-10	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	457	135.00	$61,695.00	4,730	4
2025-07-09	Onyia, Jude	Officer	Chief Scientific Officer	Direct	Sale	59,819	130.46	$7,803,986.74	18,289	4
2025-07-02	Onyia, Jude	Officer	Chief Scientific Officer	Direct	Sale	20,362	130.13	$2,649,707.06	18,289	4
2025-05-27	Gorman, Kevin Charles	Director	-	Direct	Sale	9,613	120.38	$1,157,212.94	514,596	4
2025-05-05	Rastetter, William H	Director	-	Direct	Sale	30,000	110.20	$3,306,000.00	37,491	4
2025-02-14	Roberts, Eiry	Officer	Chief Medical Officer	Direct	Sale	500	115.04	$57,520.00	35,640	4
2025-02-13	Cooke, Julie	Officer	Chief Human Resources Officer	Direct	Sale	1,551	116.78	$181,125.78	19,544	4
2025-02-13	Boyer, David W.	Officer	Chief Corp. Affairs Officer	Direct	Sale	1,785	116.74	$208,380.90	2,854	4
2025-02-13	Sherwin, Stephen A	Director	-	Direct	Sale	13,831	116.69	$1,613,939.39	10,673	4
2025-02-13	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	2,184	116.76	$255,003.84	42,474	4
2025-02-13	Benevich, Eric	Officer	Chief Commercial Officer	Direct	Sale	2,154	116.72	$251,414.88	43,784	4
2025-02-13	Gorman, Kevin Charles	Director	-	Direct	Sale	5,844	116.68	$681,877.92	521,618	4
2025-02-13	Abernethy, Matt	Officer	Chief Financial Officer	Direct	Sale	2,558	116.86	$298,927.88	34,775	4
2025-02-13	Gano, Kyle	Director,Officer	Chief Executive Officer	Direct	Sale	2,558	116.85	$298,902.30	138,872	4
2025-02-13	Onyia, Jude	Officer	Chief Scientific Officer	Direct	Sale	2,879	116.79	$336,238.41	16,846	4
2025-02-13	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	1,471	116.70	$171,665.70	4,084	4
2025-02-10	Roberts, Eiry	Officer	Chief Medical Officer	Direct	Sale	980	118.22	$115,855.60	33,253	4
2025-02-10	Boyer, David W.	Officer	Chief Corp. Affairs Officer	Direct	Sale	700	118.31	$82,817.00	1,998	4
2025-02-10	Gano, Kyle	Director,Officer	Chief Executive Officer	Direct	Sale	980	118.39	$116,022.20	137,658	4
2025-02-10	Cooke, Julie	Officer	Chief Human Resources Officer	Direct	Sale	700	118.28	$82,796.00	18,831	4
2025-02-10	Benevich, Eric	Officer	Chief Commercial Officer	Direct	Sale	980	118.31	$115,943.80	42,799	4
2025-02-10	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	911	118.25	$107,725.75	41,679	4
2025-02-10	Abernethy, Matt	Officer	Chief Financial Officer	Direct	Sale	980	118.27	$115,904.60	33,561	4
2025-02-10	Gorman, Kevin Charles	Director	-	Direct	Sale	2,274	118.37	$269,173.38	519,074	4
2025-02-03	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	623	149.29	$93,007.67	3,442	4
2025-01-31	Boyer, David W.	Officer	Chief Corp. Affairs Officer	Direct	Sale	1,104	152.94	$168,845.76	1,369	4
2025-01-31	Onyia, Jude	Officer	Chief Scientific Officer	Direct	Sale	126	152.97	$19,274.22	15,561	4
2025-01-31	Roberts, Eiry	Officer	Chief Medical Officer	Direct	Sale	1,457	152.80	$222,629.60	32,373	4
2025-01-31	Gorman, Kevin Charles	Director	-	Direct	Sale	2,707	152.92	$413,954.44	517,030	4
2025-01-31	Gano, Kyle	Director,Officer	Chief Executive Officer	Direct	Sale	1,541	152.87	$235,572.67	136,778	4
2025-01-31	Cooke, Julie	Officer	Chief Human Resources Officer	Direct	Sale	1,740	152.89	$266,028.60	18,202	4
2025-01-31	Benevich, Eric	Officer	Chief Commercial Officer	Direct	Sale	1,207	152.94	$184,598.58	41,919	4
2025-01-31	Abernethy, Matt	Officer	Chief Financial Officer	Direct	Sale	1,283	152.87	$196,132.21	32,681	4
2025-01-31	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	1,250	152.91	$191,137.50	40,863	4
2025-01-27	Gorman, Kevin Charles	Director	-	Direct	Sale	146,105	149.46	$21,836,853.30	514,596	4
2025-01-15	Gano, Kyle	Director,Officer	Chief Executive Officer	Direct	Sale	65,000	141.50	$9,197,500.00	135,392	4
2024-12-31	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	272	138.10	$37,563.20	2,507	4
2024-12-17	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	1,091	135.00	$147,285.00	2,507	4
2024-11-29	Onyia, Jude	Officer	Chief Scientific Officer	Direct	Sale	2,331	126.29	$294,381.99	15,449	4
2024-10-03	Boyer, David W.	Officer	Chief Corp. Affairs Officer	Direct	Sale	1,295	113.66	$147,189.70	377	4
2024-09-13	Boyer, David W.	Officer	Chief Corp. Affairs Officer	Direct	Sale	3,461	121.88	$421,826.68	1,672	4
2024-08-15	Rastetter, William H	Director	-	Direct	Sale	14,250	146.69	$2,090,332.50	37,491	4
2024-08-13	Abernethy, Matt	Officer	Chief Financial Officer	Direct	Sale	14,100	150.38	$2,120,358.00	31,528	4
2024-08-13	Lyons, Gary A	Director	-	Direct	Sale	11,570	150.43	$1,740,475.10	119,047	4
2024-08-13	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	7,143	150.11	$1,072,235.73	2,507	4
2024-08-06	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	273	147.70	$40,322.10	6,607	4
2024-08-01	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	2,996	154.01	$461,413.96	39,740	4
2024-08-01	Cooke, Julie	Officer	Chief Human Resources Officer	Direct	Sale	12,632	153.26	$1,935,980.32	18,202	4
2024-07-16	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	7,004	150.00	$1,050,600.00	39,740	4
2024-07-16	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	2,857	150.05	$428,692.85	6,607	4
2024-07-16	Cooke, Julie	Officer	Chief Human Resources Officer	Direct	Sale	900	150.04	$135,036.00	18,202	4
2024-07-16	Abernethy, Matt	Officer	Chief Financial Officer	Direct	Sale	900	150.04	$135,036.00	31,528	4
2024-07-16	Lyons, Gary A	Director	-	Direct	Sale	930	150.03	$139,527.90	119,047	4
2024-07-01	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	272	138.11	$37,565.92	7,507	4
2024-07-01	Cooke, Julie	Officer	Chief Human Resources Officer	Direct	Sale	10,000	140.19	$1,401,900.00	18,202	4
2024-05-31	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	273	136.55	$37,278.15	7,507	4
2024-05-29	Sherwin, Stephen A	Director	-	Direct	Sale	40,000	133.46	$5,338,400.00	26,504	4
2024-05-17	Norwalk, Leslie V	Director	-	Direct	Sale	1,106	141.82	$156,852.92	994	4
2024-05-17	Pops, Richard F	Director	-	Direct	Sale	2,100	141.84	$297,864.00	31,611	4
2024-05-17	Sharp, Shalini	Director	-	Direct	Sale	1,106	141.90	$156,941.40	994	4
2024-05-15	Abernethy, Matt	Officer	Chief Financial Officer	Direct	Sale	15,000	140.24	$2,103,600.00	31,528	4
2024-05-14	Lyons, Gary A	Director	-	Direct	Sale	12,500	135.63	$1,695,375.00	116,947	4
2024-05-06	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	273	140.55	$38,370.15	7,507	4
2024-04-15	Benevich, Eric	Officer	Chief Commercial Officer	Direct	Sale	19,818	133.36	$2,642,928.48	40,778	4
2024-04-01	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	272	137.30	$37,345.60	7,507	4
2024-03-21	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	5,000	145.06	$725,300.00	7,507	4
2024-03-14	Morrow, George J	Director	-	Direct	Sale	40,000	139.42	$5,576,800.00	0	4
2024-03-14	Benevich, Eric	Officer	Chief Commercial Officer	Direct	Sale	75,000	139.38	$10,453,500.00	40,778	4
2024-03-13	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	3,000	140.14	$420,420.00	7,507	4
2024-03-13	Pops, Richard F	Director	-	Direct	Sale	23,200	140.33	$3,255,656.00	29,512	4
2024-03-11	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	200	140.00	$28,000.00	7,507	4
2024-03-11	Pops, Richard F	Director	-	Direct	Sale	100	140.00	$14,000.00	29,512	4
2024-02-29	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	273	135.51	$36,994.23	7,507	4
2024-02-28	Benevich, Eric	Officer	Chief Commercial Officer	Direct	Sale	75,000	134.69	$10,101,750.00	40,616	4
2024-02-27	Norwalk, Leslie V	Director	-	Direct	Sale	8,000	135.67	$1,085,360.00	0	4
2024-02-20	Pops, Richard F	Director	-	Direct	Sale	15,000	132.47	$1,987,050.00	29,512	4
2024-02-13	Benevich, Eric	Officer	Chief Commercial Officer	Direct	Sale	1,098	133.01	$146,044.98	40,616	4
2024-02-13	Gorman, Kevin Charles	Director,Officer	Chief Executive Officer	Direct	Sale	2,832	133.02	$376,712.64	514,596	4
2024-02-13	Roberts, Eiry	Officer	Chief Medical Officer	Direct	Sale	1,114	132.96	$148,117.44	23,716	4
2024-02-13	Gano, Kyle	Officer	Chief Business Development Off	Direct	Sale	1,352	132.89	$179,667.28	135,166	4
2024-02-13	Onyia, Jude	Officer	Chief Scientific Officer	Direct	Sale	1,432	132.94	$190,370.08	13,128	4
2024-02-13	Boyer, David W.	Officer	Chief Corp. Affairs Officer	Direct	Sale	1,811	133.07	$240,989.77	4,895	4
2024-02-13	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	1,098	132.99	$146,023.02	39,740	4
2024-02-13	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	716	133.03	$95,249.48	7,507	4
2024-02-13	Cooke, Julie	Officer	Chief Human Resources Officer	Direct	Sale	796	133.04	$105,899.84	17,976	4
2024-02-13	Abernethy, Matt	Officer	Chief Financial Officer	Direct	Sale	1,352	132.85	$179,613.20	31,528	4
2024-02-08	Benevich, Eric	Officer	Chief Commercial Officer	Direct	Sale	980	134.19	$131,506.20	39,631	4
2024-02-08	Roberts, Eiry	Officer	Chief Medical Officer	Direct	Sale	980	134.21	$131,525.80	22,717	4
2024-02-08	Cooke, Julie	Officer	Chief Human Resources Officer	Direct	Sale	1,329	135.50	$180,079.50	17,263	4
2024-02-08	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	911	134.24	$122,292.64	38,755	4
2024-02-08	Boyer, David W.	Officer	Chief Corp. Affairs Officer	Direct	Sale	1,328	135.49	$179,930.72	4,895	4
2024-02-08	Gano, Kyle	Officer	Chief Business Development Off	Direct	Sale	980	134.20	$131,516.00	133,952	4
2024-02-08	Abernethy, Matt	Officer	Chief Financial Officer	Direct	Sale	980	134.21	$131,525.80	30,314	4
2024-02-08	Gorman, Kevin Charles	Director,Officer	Chief Executive Officer	Direct	Sale	2,274	134.15	$305,057.10	506,962	4
2024-02-01	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	623	139.77	$87,076.71	6,865	4
2024-01-31	Abernethy, Matt	Officer	Chief Financial Officer	Direct	Sale	1,283	140.72	$180,543.76	28,284	4
2024-01-31	Onyia, Jude	Officer	Chief Scientific Officer	Direct	Sale	126	141.94	$17,884.44	11,843	4
2024-01-31	Boyer, David W.	Officer	Chief Corp. Affairs Officer	Direct	Sale	2,096	140.80	$295,116.80	4,894	4
2024-01-31	Roberts, Eiry	Officer	Chief Medical Officer	Direct	Sale	1,457	140.79	$205,131.03	20,832	4
2024-01-31	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	1,250	140.65	$175,812.50	37,005	4
2024-01-31	Gorman, Kevin Charles	Director,Officer	Chief Executive Officer	Direct	Sale	2,707	140.69	$380,847.83	502,188	4
2024-01-31	Benevich, Eric	Officer	Chief Commercial Officer	Direct	Sale	1,207	140.78	$169,921.46	37,601	4
2024-01-31	Cooke, Julie	Officer	Chief Human Resources Officer	Direct	Sale	1,740	141.32	$245,896.80	17,263	4
2024-01-31	Gano, Kyle	Officer	Chief Business Development Off	Direct	Sale	1,541	140.70	$216,818.70	131,635	4
2024-01-22	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	10,000	139.86	$1,398,600.00	35,882	4
2024-01-09	Gorman, Kevin Charles	Director,Officer	Chief Executive Officer	Direct	Sale	62,023	134.01	$8,311,702.23	499,754	4
2024-01-02	Gano, Kyle	Officer	Chief Business Development Off	Direct	Sale	75,000	131.45	$9,858,750.00	130,250	4
2024-01-02	Rastetter, William H	Director	-	Direct	Sale	11,044	131.47	$1,451,954.68	51,741	4
2023-12-22	Cooke, Julie	Officer	Chief Human Resources Officer	Direct	Sale	24,000	128.39	$3,081,360.00	17,263	4
2023-12-22	Lyons, Gary A	Director	-	Direct	Sale	10,000	130.04	$1,300,400.00	193,697	4
2023-12-22	Roberts, Eiry	Officer	Chief Medical Officer	Direct	Sale	10,000	126.74	$1,267,400.00	19,521	4
2023-12-12	Roberts, Eiry	Officer	Chief Medical Officer	Direct	Sale	13,925	120.30	$1,675,177.50	29,521	4
2023-12-08	Roberts, Eiry	Officer	Chief Medical Officer	Direct	Sale	300	120.08	$36,024.00	29,521	4
2023-12-06	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	20,830	119.86	$2,496,683.80	35,882	4
2023-12-06	Roberts, Eiry	Officer	Chief Medical Officer	Direct	Sale	8,396	120.03	$1,007,771.88	29,521	4
2023-12-01	Lyons, Gary A	Director	-	Direct	Sale	5,000	116.77	$583,850.00	203,697	4
2023-11-29	Onyia, Jude	Officer	Chief Scientific Officer	Direct	Sale	2,331	113.57	$264,731.67	11,732	4
2023-11-27	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	10,919	112.27	$1,225,876.13	35,882	4
2023-10-02	Boyer, David W.	Officer	Chief Corp. Affairs Officer	Direct	Sale	1,437	112.68	$161,921.16	4,894	4
2023-09-12	Lyons, Gary A	Director	-	Direct	Sale	5,000	115.02	$575,100.00	203,697	4
2023-09-01	Cooke, Julie	Officer	Chief Human Resources Officer	Direct	Sale	824	110.93	$91,406.32	17,263	4
2023-09-01	Lyons, Gary A	Director	-	Direct	Sale	5,000	110.06	$550,300.00	203,697	4
2023-08-30	Boyer, David W.	Officer	Chief Corp. Affairs Officer	Direct	Sale	2,733	107.56	$293,961.48	3,460	4
2023-08-28	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	1,431	107.52	$153,861.12	5,931	4
2023-08-21	Gano, Kyle	Officer	Chief Business Development Off	Direct	Sale	2,132	107.41	$228,998.12	130,250	4
2023-08-21	Gorman, Kevin Charles	Director,Officer	Chief Executive Officer	Direct	Sale	9,328	107.40	$1,001,827.20	499,754	4
2023-08-21	Boyer, David W.	Officer	Chief Corp. Affairs Officer	Direct	Sale	1,600	107.41	$171,856.00	6,193	4
2023-08-21	Benevich, Eric	Officer	Chief Commercial Officer	Direct	Sale	1,600	107.40	$171,840.00	36,436	4
2023-08-21	Cooke, Julie	Officer	Chief Human Resources Officer	Direct	Sale	2,132	107.41	$228,998.12	18,087	4
2023-08-21	Lippoldt, Darin	Officer	Chief Legal Officer	Direct	Sale	2,132	107.39	$228,955.48	46,991	4
2023-08-21	Onyia, Jude	Officer	Chief Scientific Officer	Direct	Sale	3,198	107.37	$343,369.26	9,638	4
2023-08-21	Abernethy, Matt	Officer	Chief Financial Officer	Direct	Sale	2,132	107.39	$228,955.48	27,131	4
2023-08-21	Delaet, Ingrid	Officer	Chief Regulatory Officer	Direct	Sale	1,404	107.42	$150,817.68	4,645	4
2023-08-21	Roberts, Eiry	Officer	Chief Medical Officer	Direct	Sale	3,198	107.38	$343,401.24	29,521	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

91.27%

Inst. Shares: 91,721,782

Shares Outstanding: 100,500,000

2025-12-31

94.15%

Inst. Shares: 93,677,210

Shares Outstanding: 99,500,000

2025-09-30

91.31%

Inst. Shares: 90,763,070

Shares Outstanding: 99,400,000

2025-06-30

92.45%

Inst. Shares: 91,521,160

Shares Outstanding: 99,000,000

2025-03-31

88.85%

Inst. Shares: 88,586,396

Shares Outstanding: 99,700,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	91,721,782	100,500,000	91.27%
2025-12-31	93,677,210	99,500,000	94.15%
2025-09-30	90,763,070	99,400,000	91.31%
2025-06-30	91,521,160	99,000,000	92.45%
2025-03-31	88,586,396	99,700,000	88.85%
2024-12-31	88,847,610	100,400,000	88.49%
2024-09-30	87,572,715	101,100,000	86.62%
2024-06-30	88,573,800	100,800,000	87.87%
2024-03-31	84,977,237	99,800,000	85.15%
2023-12-31	85,103,766	97,700,000	87.11%
2023-09-30	84,715,695	97,900,000	86.53%
2023-06-30	84,712,132	97,600,000	86.80%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

NEUROCRINE BIOSCIENCES INC (NBIX) — SEC Financial Statements & Analysis

NEUROCRINE BIOSCIENCES INC (NBIX) is a biological products, (no diagnostic substances) company, incorporated in DE. NEUROCRINE BIOSCIENCES INC trades on NBIX: Nasdaq as: NBIX. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), NEUROCRINE BIOSCIENCES INC reported a 28.59% year-over-year revenue growth, a Gross Profit Margin of 98.17% (TTM), a Debt-to-Equity ratio of 0.44x, a Price-to-Sales (P/S) ratio of 4.27x (TTM), a Price-to-Book (P/B) ratio of 3.89 (TTM), at a market cap of $13.24B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 28.59%
Gross Profit Margin TTM: 98.17%
Debt To Equity: 0.44x
P/S TTM: 4.27x
P/B TTM: 3.89
Market Cap: $13.24B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is NEUROCRINE BIOSCIENCES INC in?

NEUROCRINE BIOSCIENCES INC (NBIX) operates in the Biological Products, (No Diagnostic Substances) industry.

What is NBIX's market cap?

NEUROCRINE BIOSCIENCES INC (NBIX) has a market capitalization of $13.24B as of 2026-03-31.

What is NBIX's P/E ratio?

NEUROCRINE BIOSCIENCES INC (NBIX)'s trailing twelve month P/E ratio is 19.80x as of 2026-03-31.

What exchange does NBIX trade on?

NEUROCRINE BIOSCIENCES INC (NBIX) trades on the NBIX: Nasdaq.

Where is NEUROCRINE BIOSCIENCES INC incorporated?

NEUROCRINE BIOSCIENCES INC is incorporated in DE.

NEUROCRINE BIOSCIENCES INC (NBIX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.